



**EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY
PRODUCTS AND PIPELINE AT 52ND ASCO ANNUAL MEETING**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of
ab

Lenvatinib (Lenvima)	Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC).
Abstract No: 4553	Poster Presentation June 6 (Mon), 13:00-16:30

Lenvatinib (Lenvima) Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer:

Abstract No: 6088